Shenqi compound ameliorates type-2 diabetes mellitus by modulating the gut microbiota and metabolites

J Chromatogr B Analyt Technol Biomed Life Sci. 2022 Apr 1:1194:123189. doi: 10.1016/j.jchromb.2022.123189. Epub 2022 Feb 24.

Abstract

The gut microbiota (GM) and metabolites are important factors in mediating the development of type-2 diabetes mellitus (T2DM). An imbalance in the gut microbiota and metabolites can disrupt the function of the intestinal barrier, cause changes in the permeability of the intestinal mucosa and promote the immune inflammatory response, thereby aggravating the fluctuation of blood glucose level and promoting the occurrence and development of the chronic complications of DM. Manipulating the GM and metabolites is a promising therapeutic intervention and is being studied extensively. Shenqi compound (SQC) is a traditional Chinese medicine formulation, which has been widely used to improve T2DM. Studies have demonstrated that SQC can reduce glycemic variability, alleviate the inflammatory response, etc. However, its underlying mechanism remains unknown. Therefore, in this experiment, We administered SQC to Goto-Kakizaki (GK) rats and evaluated its effect on blood glucose homeostasis and the intestinal mucosal barrier. We identified the profiles of the GM and metabolites with the aid of 16S rDNA gene sequencing and non-target metabolomics analysis. It showed that SQC intervention could reduce glycemic variability, regulate serum levels of glucagon and insulin, and improve injury to the intestinal mucosal barrier of GK rats. In the gut, the ratio of bacteria of the phyla Bacteroidetes/Firmicutes could be improved after SQC intervention. SQC also regulated the relative abundance of Prevotellaceae, Butyricimonas, Bacteroides, Blautia, Roseburia, Lactobacillus, and Rothia. We found out that expression of 40 metabolites was significantly improved after SQC intervention. Further analyses of metabolic pathways indicated that the therapeutic effect of SQC might be related predominantly to its ability to improve gluconeogenesis/glycolysis, amino acid metabolism, lipid metabolism, citrate cycle, and butanoate metabolism. These results suggest that SQC may exert a beneficial role in T2DM by modulating the GM and metabolites in different pathways.

Keywords: Glycemic variability; Gut microbiota; Intestinal mucosal barrier; Metabolites; Shenqi compound; Type 2 diabetes mellitus.

MeSH terms

  • Amino Acids / metabolism
  • Animals
  • Bacteria / classification
  • Bacteria / drug effects
  • Bacteria / genetics
  • Bacteria / isolation & purification
  • Blood Glucose / metabolism*
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Diabetes Mellitus, Type 2 / metabolism
  • Diabetes Mellitus, Type 2 / microbiology*
  • Diabetes Mellitus, Type 2 / physiopathology
  • Drugs, Chinese Herbal / administration & dosage*
  • Gastrointestinal Microbiome / drug effects*
  • Gluconeogenesis / drug effects
  • Glycolysis / drug effects
  • Humans
  • Insulin / blood
  • Male
  • Rats
  • Rats, Wistar

Substances

  • Amino Acids
  • Blood Glucose
  • Drugs, Chinese Herbal
  • Insulin
  • shenqi